Report of Foreign Issuer (6-k)
January 17 2017 - 08:18AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
16 January
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc
(the
'Company'
)
Transaction
notification
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Sir
Andrew Witty
|
b)
|
Position/status
|
Chief
Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
406.772
(personal contribution)
|
£15.66
|
406.759
(personal contribution)
|
£15.66
|
203.865
(personal contribution)
|
£15.66
|
203.865
(personal contribution)
|
£15.66
|
510.713
(personal contribution)
|
£15.66
|
406.772
(matching shares)
|
£15.66
|
406.759
(matching shares)
|
£15.66
|
203.865
(matching shares)
|
£15.66
|
203.865
(matching shares)
|
£15.66
|
510.713
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
3,463.948
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Ms E
Walmsley
|
b)
|
Position/status
|
CEO
Designate
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
89.065
(personal contribution)
|
£15.66
|
89.065
(personal contribution)
|
£15.66
|
71.015
(personal contribution)
|
£15.66
|
71.015
(personal contribution)
|
£15.66
|
175.863
(personal contribution)
|
£15.66
|
175.850
(personal contribution)
|
£15.66
|
89.065
(matching shares)
|
£15.66
|
89.065
(matching shares)
|
£15.66
|
71.015
(matching shares)
|
£15.66
|
71.015
(matching shares)
|
£15.66
|
175.863
(matching shares)
|
£15.66
|
175.850
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,343.746
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr R G
Connor
|
b)
|
Position/status
|
President,
Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
79.620
(personal contribution)
|
£15.66
|
79.607
(personal contribution)
|
£15.66
|
52.007
(personal contribution)
|
£15.66
|
52.007
(personal contribution)
|
£15.66
|
119.484
(personal contribution)
|
£15.66
|
79.620
(matching shares)
|
£15.66
|
79.607
(matching shares)
|
£15.66
|
52.007
(matching shares)
|
£15.66
|
52.007
(matching shares)
|
£15.66
|
119.484
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
765.45
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr S
Dingemans
|
b)
|
Position/status
|
Chief
Financial Officer
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
192.213
(personal contribution)
|
£15.66
|
76.874
(personal contribution)
|
£15.66
|
99.193
(personal contribution)
|
£15.66
|
99.180
(personal contribution)
|
£15.66
|
232.242
(personal contribution)
|
£15.66
|
232.229
(personal contribution)
|
£15.66
|
192.213
(matching shares)
|
£15.66
|
76.874
(matching shares)
|
£15.66
|
99.193
(matching shares)
|
£15.66
|
99.180
(matching shares)
|
£15.66
|
232.242
(matching shares)
|
£15.66
|
232.229
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,863.862
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr N
Hirons
|
b)
|
Position/status
|
SVP,
Global Ethics & Compliance
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
36.414
(personal contribution)
|
£15.66
|
36.414
(personal contribution)
|
£15.66
|
85.869
(personal contribution)
|
£15.66
|
85.869
(personal contribution)
|
£15.66
|
36.414
(matching shares)
|
£15.66
|
36.414
(matching shares)
|
£15.66
|
85.869
(matching shares)
|
£15.66
|
85.869
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
489.132
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr S A
Hussain
|
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
116.783
(personal contribution)
|
£15.66
|
171.654
(personal contribution)
|
£15.66
|
202.916
(personal contribution)
|
£15.66
|
202.916
(personal contribution)
|
£15.66
|
116.783
(matching shares)
|
£15.66
|
171.654
(matching shares)
|
£15.66
|
202.916
(matching shares)
|
£15.66
|
202.916
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,388.538
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S
Redfern
|
b)
|
Position/status
|
Chief
Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
72.618
(personal contribution)
|
£15.66
|
72.605
(personal contribution)
|
£15.66
|
58.351
(personal contribution)
|
£15.66
|
58.351
(personal contribution)
|
£15.66
|
109.284
(personal contribution)
|
£15.66
|
109.284
(personal contribution)
|
£15.66
|
72.618
(matching shares)
|
£15.66
|
72.605
(matching shares)
|
£15.66
|
58.351
(matching shares)
|
£15.66
|
58.351
(matching shares)
|
£15.66
|
109.284
(matching shares)
|
£15.66
|
109.284
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
960.986
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr M M
Slaoui
|
b)
|
Position/status
|
Chairman,
Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 12 January 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$39.01
|
125.340
(personal contribution)
|
$39.01
|
125.327
(personal contribution)
|
$39.01
|
78.047
(personal contribution)
|
$39.01
|
78.047
(personal contribution)
|
$39.01
|
128.475
(personal contribution)
|
$39.01
|
128.475
(personal contribution)
|
$39.01
|
125.340
(matching shares)
|
$39.01
|
125.327
(matching shares)
|
$39.01
|
78.047
(matching shares)
|
$39.01
|
78.047
(matching shares)
|
$39.01
|
128.475
(matching shares)
|
$39.01
|
128.475
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,327.422
$39.01
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Ms C
Thomas
|
b)
|
Position/status
|
SVP,
Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
90.103
(personal contribution)
|
£15.66
|
78.542
(personal contribution)
|
£15.66
|
78.530
(personal contribution)
|
£15.66
|
159.879
(personal contribution)
|
£15.66
|
159.879
(personal contribution)
|
£15.66
|
90.103
(matching shares)
|
£15.66
|
78.542
(matching shares)
|
£15.66
|
78.530
(matching shares)
|
£15.66
|
159.879
(matching shares)
|
£15.66
|
159.879
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,133.866
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr P C
Thomson
|
b)
|
Position/status
|
SVP,
Communications & Government Affairs
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
54.266
(personal contribution)
|
£15.66
|
53.347
(personal contribution)
|
£15.66
|
97.819
(personal contribution)
|
£15.66
|
54.266
(matching shares)
|
£15.66
|
53.347
(matching shares)
|
£15.66
|
97.819
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
410.864
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D E
Troy
|
b)
|
Position/status
|
SVP
& General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 12 January 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$39.01
|
50.726
(personal contribution)
|
$39.01
|
50.726
(personal contribution)
|
$39.01
|
40.386
(personal contribution)
|
$39.01
|
40.386
(personal contribution)
|
$39.01
|
90.932
(personal contribution)
|
$39.01
|
90.932
(personal contribution)
|
$39.01
|
50.726
(matching shares)
|
$39.01
|
50.726
(matching shares)
|
$39.01
|
40.386
(matching shares)
|
$39.01
|
40.386
(matching shares)
|
$39.01
|
90.932
(matching shares)
|
$39.01
|
90.932
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
728.176
$39.01
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr P J
T Vallance
|
b)
|
Position/status
|
President,
Pharmaceuticals R&D
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.66
|
161.014
(personal contribution)
|
£15.66
|
161.001
(personal contribution)
|
£15.66
|
115.614
(personal contribution)
|
£15.66
|
115.614
(personal contribution)
|
£15.66
|
188.068
(personal contribution)
|
£15.66
|
188.068
(personal contribution)
|
£15.66
|
161.014
(matching shares)
|
£15.66
|
161.001
(matching shares)
|
£15.66
|
115.614
(matching shares)
|
£15.66
|
115.614
(matching shares)
|
£15.66
|
188.068
(matching shares)
|
£15.66
|
188.068
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,858.758
£15.66
|
e)
|
Date of
the transaction
|
2017-01-12
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: January
16, 2017
|
|
|
|
|
By: VICTORIA
WHYTE-
-------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024